BioSpace News Archive

The Breakthrough Devices Program is designed to give patients and health care providers timely access to medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

As the country’s leading provider of clinical analytics solutions to reduce medical misdiagnoses, Covera Health announced its Series B financing, led by Insight Partners, with participation from existing investors, including New York-based Prism Ventures.

Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that its WatchPAT has been selected for inclusion in the Weizmann Institute’s Project 10K.

Paradromics, together with partner Caeleste, have developed a novel mixed-signal sensor technology that enables high data rate neural recordings with 60 times lower power consumption than conventional digital readouts.

Physicians’ Education Resource® (PER®), a leading resource for continuing medical education, will host the 2nd Annual Precision Medicine Symposium: An Illustrated Tumor Board.

Recursion, a digital biology company industrializing drug discovery, will present a company update at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco o

Cardinal Analytx Solutions, an artificial intelligence (AI)-enabled health insights company, today announced that it has rebranded as Prealize.

BTIG announced today that the “BTIG Targeted Therapeutics Conference” will take place on Monday, February 24, 2020 in New York

Nearly 11,900 people provided the lifesaving gift of organ donation upon their death last year, making 2019 the ninth consecutive record-breaking year for deceased donation in the United States.

Elysium Health, Inc.™, a life sciences company developing clinically validated health products based on advancements in scientific research, today announced the initiation of a clinical trial at Duke Clinical Research Institute to study correlations between biological age and circulating NAD+ levels in healthy adults, in addition to other clinical biomarkers that have been implicated in aging.